Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.74 |
| ▸ | MEN1 | O00255 | 10/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034437 | 0.90 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL8711180 | 0.88 | ALOX5 (0.64) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL18027779 | 0.88 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL18993399 | 0.87 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL9337489 | 0.87 | MEN1 (0.64) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL9497852 | 0.86 | ALDH1A1 (0.75) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL18010133 | 0.84 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL28456010 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL7376491 | 0.84 | ABCB1 (0.59) | ALDH1A1CYP3A4TSHRTDP1KMT2A | |
| SCHEMBL8303947 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP3A4TSHRTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885CYP3A4 2599/4885TSHR 2294/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885CYP3A4 2599/4885TSHR 2294/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885CYP3A4 2599/4885TSHR 2294/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885CYP3A4 2599/4885TSHR 2294/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | ALDH1A1 2519/4885CYP3A4 2599/4885TSHR 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.